Time and dose relationships between schisandrin B- and schisandrae fructus oil-induced hepatotoxicity and the associated elevations in hepatic and serum triglyceride levels in mice

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1429-1439

  Zhang, Yi ^a   Pan, Si Yuan ^a   Zhou, Shu Feng ^b   Wang, Xiao Yan ^a   Sun, Nan ^a   Zhu, Pei Li ^a   Chu, Zhu Sheng ^a   Yu, Zhi Ling ^c   Ko, Kam Ming ^d  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^d HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Affinity; Alanine aminotransaminase; Hepatomegaly; Maximum effect; Pharmacodynamics

Indexed keywords

ALANINE AMINOTRANSFERASE; MALONALDEHYDE; SCHISANDRAE FRUCTUS OIL; SCHIZANDRIN B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VEGETABLE OIL; CYCLOOCTANE DERIVATIVE; LIGNAN; POLYCYCLIC HYDROCARBON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; HEPATOMEGALY; LIVER INJURY; LIVER LEVEL; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; RECEPTOR AFFINITY; SCHISANDRA; SCHISANDRAE FRUCTUS; TOXICITY TESTING; UPREGULATION; WEIGHT REDUCTION; ANIMAL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TIME;

ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ANIMALS; CYCLOOCTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; LIGNANS; LIVER; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; PLANT OILS; POLYCYCLIC COMPOUNDS; SCHISANDRA; TIME FACTORS; TRIGLYCERIDES;

EID: 84908070612     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S67518     Document Type: Article

References (34)

1. Fosdick A, Zheng J, Pflanz S, et al. Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014;348(1):96-105.
2. Arpon DR, Gandhi MK, Martin JH. A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. Br J Clin Pharmacol. 2014;78(2):274-281.
3. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009;101(22):1543-1552.
4. Rezende VM, Rivellis A, Novaes MM, de Alencar Fisher Chamone D, Bendit I. Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Des Devel Ther. 2013;7:699-710.
5. Yoon S, Lee H, Kim TE, et al. Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers. Drug Des Devel Ther. 2014;8:123-128.
6. Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012;6:71-79.
7. Salphati L, Wong H, Belvin M, et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 2010;38(9):1436-1442.
8. Betts AM, Clark TH, Yang J, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010;333(1):2-13.
9. Romero E, Vélez de Mendizabal N, Cendrós JM, et al. Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. J Pharmacol Exp Ther. 2012;342(3):788-798.
10. Ahmed AA, Marki A, Gaspar R, et al. β(2)-Adrenergic activity of 6-methoxykaempferol-3-O-glucoside on rat uterus: in vitro and in silico studies. Eur J Pharmacol. 2011;667(1-3):348-354.
11. Alvarez-Jaimes L, Sutton SW, Nepomuceno D, et al. In vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependency. PLoS One. 2012;7(2):e30792.
12. Corboz MR, Rivelli MA, Shah H, et al. Role of α2-adrenoceptors in electrical field stimulation-induced contraction of pig nasal mucosa and pharmacologic characterization of a novel α2C-adrenoceptor agonist. Am J Rhinol Allergy. 2013;27(2):84-90.
13. Zhang YZ, An R, Yuan J, Wang Y, Gu QQ, Wang XH. [Analysis and comparison of intestinal absorption of components of Gegenqinlian decoction in different combinations based on pharmacokinetic parameters]. Yao Xue Xue Bao. 2013;48(10):1611-1617. Chinese.
14. Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine. 2002;9(Suppl 3):1-33.
15. Pan SY, Han YF. Comparison of the inhibitory efficacy of four belladonna drugs on gastrointestinal movement and cognitive function in food-deprived mice. Pharmacology. 2004;72(3):177-183.
16. Pan SY, Dong H, Guo BF, et al. Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate. Naunyn Schmiedebergs Arch Pharmacol. 2011;383(6):585-591.
17. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681.
18. Panossian A, Wikman G. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnopharmacol. 2008;118(2):183-212.
19. Pan SY, Dong H, Han YF, Li WY, Zhao XY, Ko KM. A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. Eur J Pharmacol. 2006;537(1-3):200-204.
20. Pan SY, Jia ZH, Zhang Y, et al. Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture. J Pharmacol Sci. 2013;123(2):110-119.
21. Ip SP, Poon MK, Wu SS, et al. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Med. 1995;61(5):398-401.
22. Trevaskis NL, Charman WN, Porter CJ. Acute hypertriglyceridemia promotes intestinal lymphatic lipid and drug transport: a positive feedback mechanism in lipid and drug absorption. Mol Pharm. 2011;8(4):1132-1139.
23. Bartlett K, Eaton S. Mitochondrial beta-oxidation. Eur J Biochem. 2004;271(3):462-469.
24. Kwan HY, Hu YM, Chan CL, et al. Lipidomics identification of metabolic biomarkers in chemically induced hypertriglyceridemic mice. J Proteome Res. 2013;12(3):1387-1398.
25. An LP, Wang YP, Liu XM, et al. [Effect of Schisandrae fructus oil on type 2 diabetic rats induced by streptozotocin]. Chin Tradit Herbal Drugs. 2012;43(3):552-556. Chinese.
26. Hou DY, Hui RH, Li TC, Diao QP. [Determination of fatty acids and octadecadienoic acid in Schisandra chinensis]. J Anshan Normal Univ. 2011;(2):26-29. Chinese.
27. Zhang T, Bo J, Xu W, Geng, N. [Analysis of fatty acids composition in the oil of schisandra chinensis by GC-MS]. J Cent Univ Nat (Nat Sci Edition). 2012;2(21):29-31. Chinese.
28. Buang Y. The mechanism of hepatomegaly associated with hepatic steatosis. J Pharm Res. 2011;4(12):4404-4407.
29. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114(4):842-845.
30. Lam PY, Leong PK, Chen N, Ko KM. Schisandrin B enhances the glutathione redox cycling and protects against oxidant injury in different types of cultured cells. Biofactors. 2011;37(6):439-446.
31. Chang CY, Chen YL, Yang SC, et al. Effect of schisandrin B and sesamin mixture on CCl(4)-induced hepatic oxidative stress in rats. Phytother Res. 2009;23(2):251-256.
32. Pan SY, Zhou SF, Gao SH, et al. New perspectives on how to discover drugs from herbal medicines: CAM's outstanding contribution to modern therapeutics. Evid Based Complement Alternat Med. 2013;2013: 627375.
33. Smejkal K, Slapetová T, Krmenčík P, et al. Evaluation of cytotoxic activity of Schisandra chinensis lignans. Planta Med. 2010;76(15): 1672-1677.
34. Chyau CC, Ker YB, Chang CH, et al. Schisandra chinensis peptidoglycan-assisted transmembrane transport of lignans uniquely altered the pharmacokinetic and pharmacodynamic mechanisms in human HepG2 cell model. PLoS One. 2014;9(1):e85165.